Voruciclib(P1446A-05) is a small molecule flavone derivative, a pan inhibitor of CDK with Ki’s of 0.626 nM-9.1nM, that potently targets CDK9, represses expression of MCL-1 and leads to tumor cell apoptosis and tumor growth inhibition in multiple models of diffuse large B-cell lymphoma (DLBCL).

Mavoglurant (AFQ056) is a structurally selective, non-competitive antagonist of mGlu5 receptor with an IC50 of 30 nM. It exhibits efficacy in treatment of L-dopa induced dyskinesia in Parkinson’s disease and Fragile X syndrome.

G-5555 is a selective inhibitor of Group I p21-activated kinases (PAKs), including PAK1, PAK2, and PAK3, with Ki values of 3.7 nM for PAK1 and 11 nM for PAK2.

Valspodar is a second-generation, non-immunosuppressive inhibitor of P-glycoprotein (Pgp) that reverses multidrug resistance by blocking drug efflux. It enhances the intracellular accumulation of chemotherapeutics like mitoxantrone, restoring drug sensitivity in resistant cancer cells.

LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively.